Castle Biosciences Inc

  • Earnings Score
  • Moat Score
  • Safety Score
  • Market Cap $473.77M
  • PE -93
  • Debt $11.31M
  • Cash $89.69M
  • EV $395.39M
  • FCF $41.75M

Earnings

loading chart...

Sales & Net Margins

loading chart...
Earnings-$5.07M
EBIT-$15.12M
ROE-1%
ROA-3%
FCF$41.75M
Equity$440.31M
Growth Stability1
PE-93.46
PB1.08
P/FCF11.35
P/S1.36
Price/Cash0.19
Debt/Equity0.03
Debt/FCF0.27
Net Margins-29%
Gross Margins82%
Op. Margins-4%
Earnings CAGR2%
Sales Growth YoY21%
Sales Growth QoQ2%
Sales CAGR48%
FCF CAGR6%
Equity CAGR27%
Earnings Stability-0.31
Earnings Growth YoY920%
Earnings Growth QoQ-370%
Sales CAGR 5Y49%
FCF CAGR 5Y14%
Equity CAGR 5Y11%
Earnings CAGR 3Y56%
Sales CAGR 3Y56%
FCF CAGR 3Y5%
Equity CAGR 3Y4%
Market Cap$473.77M
Revenue$347.08M
Assets$501.72M
Total Debt$11.31M
Cash$89.69M
Shares Outstanding28.61M
EV395.39M
Earnings Score6%
Moat Score7%
Safety Score98%
Final Score37%
Working Capital312.11M
Current Ratio9.37
Gross Profit$284.39M
Shares Growth 3y4%
Equity Growth QoQ-3%
Equity Growth YoY9%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...
Castle Biosciences Inc is a commercial-stage dermatological cancer company. It is focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The product portfolio of the company includes Cutaneous Melanoma, DecisionDx-Melanoma, DecisionDx-CMSeq, and DecisionDx-PRAME among others.

SEC Filings

Direct access to Castle Biosciences Inc (CSTL) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

  • 2025
    • 10-Q Mar 31
  • 2024
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31
  • 2023
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31

Sector Comparison

How does Castle Biosciences Inc compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Castle Biosciences Inc compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

CAGR 2%
Stability -31%
loading chart...

Castle Biosciences Inc Discounted Cash Flow

Fully customizable DCF calculator online for Castle Biosciences Inc.

= $645M
012345678910TV
fcf$42M$44M$47M$50M$53M$57M$60M$64M$68M$72M$77M$771M
DCF$40M$39M$38M$36M$35M$34M$33M$32M$31M$30M$297M
Value$645M

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years12/201812/201912/202012/202112/202212/202312/2024TTM
Net Margins-45%6%-16%-33%-49%-26%5%-29%
ROA-8%-1%-9%-15%-13%2%-3%
ROE-4%-2%-8%-17%-15%4%-1%

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years12/201812/201912/202012/202112/202212/202312/2024TTM
Debt over FCF-5.350---00.290.27
Debt over Equity-0.430.380--00.020.03
Growth Stability-------1

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years12/201812/201912/202012/202112/202212/202312/2024CAGR 5Y
Revenue YoY growth-128%21%50%46%60%51%49%
Earnings YoY growth--129%-444%204%115%-14%-132%-
Equity YoY growth--250%388%-1%-3%-2%17%11%
FCF YoY growth--148%-16%-539%110%-59%-290%14%